{"id":"NCT02935192","sponsor":"Institute of Virology, Vaccines and Sera, Torlak","briefTitle":"Phase 3 Trial of Serbian Seasonal Influenza Vaccine","officialTitle":"A Phase 3 Double Blinded, Randomized, Placebo- Controlled Study to Examine the Safety and Immunogenicity of a Seasonal Trivalent Split Inactivated Influenza Vaccine Produced by Institute Torlak in 18-65 Year Old Volunteers in Serbia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-28","primaryCompletion":"2017-01-08","completion":"2017-03-25","firstPosted":"2016-10-17","resultsPosted":"2019-04-19","lastUpdate":"2019-04-19"},"enrollment":480,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Vaccine","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Vaccine Arm","type":"EXPERIMENTAL"},{"label":"Placebo Arm","type":"PLACEBO_COMPARATOR"}],"summary":"A Phase 3, double-blind, randomized, placebo-controlled trial of a seasonal, trivalent, split, inactivated influenza vaccine produced by InstituteTorlak.","primaryOutcome":{"measure":"Number of Participants With Solicited Adverse Events (Local & Systemic Reactogenicity)","timeFrame":"30-minute post-vaccination period","effectByArm":[{"arm":"Vaccine Arm","deltaMin":5,"sd":null},{"arm":"Placebo Arm","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":15},"locations":{"siteCount":6,"countries":["Serbia"]},"refs":{"pmids":["32518891"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":312},"commonTop":["Respiratory tract infection","Nasopharyngitis","Rhinitis"]}}